StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

No gross margin figures for Protagonist Therapeutics

Protagonist Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Protagonist Therapeutics figures

See a number that looks wrong?